Drug Profile
Research programme: indomethacin/phosphatidylcholine - PLx Pharma/UTHealth
Alternative Names: Phosphatidylcholine-enriched indomethacinLatest Information Update: 02 Apr 2012
Price :
$50
*
At a glance
- Originator PLx Pharma; University of Texas Health Science Center at Houston
- Class Nonsteroidal anti-inflammatories; Phospholipids
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Congenital heart defects
Most Recent Events
- 30 Mar 2012 Investigation in Congenital heart disorders in USA (unspecified route)